Pancreatic Cancer Research

ResearcherBC Cancer AgencyActive in the last 2 years

Sharlene Gill

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3306-3617; OpenAlex author ID A5070331492. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 0, last author 5)
Trials
1
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 2 papers · 2013: none · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 17

  1. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarc… Co-author DOI 10.1038/s41467-026-70120-z↗
  2. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  3. Canadian National Pancreas Conference 2025: Recent Advances in Patient-Centred Management of Pancreatic Cancer. Co-author DOI 10.3390/curroncol33100629↗
  4. Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. Co-author DOI 10.3390/curroncol31100461↗
  5. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal a… Co-author DOI 10.1038/s41467-022-32591-8↗
  6. Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. Last author DOI 10.21037/jgo-20-422↗
  7. Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000500↗
  8. Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer. Last author DOI 10.1097/coc.0000000000000625↗
  9. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-0191↗
  10. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. Co-author DOI 10.1097/coc.0000000000000193↗
  11. Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospect… Last author DOI 10.1097/coc.0000000000000205↗
  12. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-con… Last author DOI 10.1016/j.ctrv.2016.09.001↗
  13. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have R… Co-author DOI 10.1200/jco.2016.68.5776↗
  14. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2014.04.008↗
  15. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. Co-author DOI 10.1186/1471-2407-14-471↗
  16. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Co-author DOI 10.1007/s10637-010-9611-3↗
  17. Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience. Last author DOI 10.1097/coc.0b013e318209d36c↗

Trials 1

  1. AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Study chair NCT00265876↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel John Renouf · 10 shared papers, 2012–2026 · strength 1.07
  2. Christina Kim · 6 shared papers, 2012–2026 · strength 0.86
  3. Ravi Ramjeesingh · 4 shared papers, 2022–2026 · strength 0.70
  4. Derek J. Jonker · 5 shared papers, 2012–2026 · strength 0.62
  5. George Zogopoulos · 3 shared papers, 2024–2026 · strength 0.61
  6. Erica S. Tsang · 4 shared papers, 2019–2026 · strength 0.61
  7. James Thomas Topham · 4 shared papers, 2019–2026 · strength 0.60
  8. Jennifer Jane Knox · 4 shared papers, 2019–2026 · strength 0.60
  9. David F. Schaeffer · 4 shared papers, 2019–2026 · strength 0.60
  10. Mustapha Ali Tehfe · 3 shared papers, 2022–2026 · strength 0.54
  11. Petr Kavan · 3 shared papers, 2022–2026 · strength 0.54
  12. Félix Couture · 3 shared papers, 2022–2026 · strength 0.54
  13. Chris J. O’Callaghan · 3 shared papers, 2022–2026 · strength 0.54
  14. Joanna M. Karasinska · 3 shared papers, 2019–2026 · strength 0.48
  15. Jessica L. Nickerson · 2 shared papers, 2024–2026 · strength 0.41
  16. Yoo‐Joung Ko · 3 shared papers, 2016–2026 · strength 0.38
  17. Winson Y. Cheung · 4 shared papers, 2017–2019 · strength 0.36
  18. Steve Gallinger · 2 shared papers, 2019–2026 · strength 0.27
  19. Orçun Haçarız · 1 shared paper, 2026 · strength 0.24
  20. Pablo E. Serrano · 1 shared paper, 2026 · strength 0.24
  21. Saman Maleki Vareki · 1 shared paper, 2026 · strength 0.24
  22. Popi Kasvis · 1 shared paper, 2026 · strength 0.24
  23. Ken A. Leslie · 1 shared paper, 2026 · strength 0.24
  24. Malcolm J. Moore · 4 shared papers, 1 shared trial, 2006–2019 · strength 0.22
  25. Faiyaz Notta · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.